Filtered By:
Cancer: Adenocarcinoma
Drug: Proton Pump Inhibitors PPIs
This page shows you your search results in order of date.
Order by Relevance | Date
Total 55 results found since Jan 2013.
Identifying a selective inhibitor of autophagy that targets ATG12-ATG3 protein-protein interaction
We describe a lead compound (#189) that inhibited GFP-fused MAP1LC3B/LC3B (microtubule associated protein 1 light chain 3 beta) puncta formation in cells with IC50 value corresponding to 9.3 μM. This compound displayed a selective inhibitory effect on the growth of autophagy addicted tumor cells and inhibited secretion of IL1B/IL-1β (interleukin 1 beta) by macrophage-like cells. Compound 189 has the potential to be developed into a therapeutic drug and its discovery documents the power of targeting PPIs for acquiring specific and selective compound inhibitors of autophagy.Abbreviations: ANOVA: analysis of variance; ATG: ...
Source: Autophagy - May 15, 2023 Category: Cytology Authors: Gal Chaim Nuta Yuval Gilad Nadav Goldberg Sara Meril Marcela Bahlsen Silvia Carvalho Noga Kozer Haim Barr Yael Fridmann Sirkis Kamil Herc ík Petra B řehová Radim Nencka Shani Bialik Miriam Eisenstein Adi Kimchi Source Type: research
Updates on Surgical Treatment for Gastroesophageal Reflux Disease
Am Surg. 2023 Feb 14:31348231157414. doi: 10.1177/00031348231157414. Online ahead of print.ABSTRACTGastroesophageal reflux disease (GERD) is a common condition that is on the rise. Obesity is one risk factor that has increased in parallel with the rise of GERD. Typical symptoms include heartburn, regurgitation, dysphagia, cough, and chest pain. Patients with typical symptoms are empirically treated with proton pump inhibitors (PPIs). If the diagnosis is not clear, further evaluation is performed with endoscopy, pH monitoring, and esophageal manometry. Untreated GERD increases the risk of esophagitis, esophageal stricture, ...
Source: The American Surgeon - February 15, 2023 Category: Surgery Authors: Katherine Kendrick Shanu N Kothari Source Type: research
Barrett Esophagus: Rapid Evidence Review
Am Fam Physician. 2022 Oct;106(4):383-387.ABSTRACTBarrett esophagus is a premalignant change of the esophagus; however, malignant transformation to esophageal adenocarcinoma is rare in patients without dysplasia. Barrett esophagus is estimated to affect up to 5.6% of the U.S. population. Risk factors for Barrett esophagus include gastroesophageal reflux disease, obesity, age older than 50 years, male sex, tobacco use, and a family history of Barrett esophagus or esophageal adenocarcinoma. Patients who experience chronic gastroesophageal reflux symptoms plus additional risk factors should be considered for screening. Mucosa...
Source: American Family Physician - October 19, 2022 Category: Primary Care Authors: Carl Bryce Merima Bucaj Renee Gazda Source Type: research
